Breaking away from dopamine defi ciency: An essential new direction for Parkinson ' s disease

Reviews in the Neurosciences

Volumn 23, Issue 4, 2012, Pages 403-428

  Willis, Gregory L ^a   Moore, Cleo ^a   Armstrong, Stuart M ^a  

^a Bronowski Institute of Behavioural Neuroscience   (Australia)

Author keywords

Adverse effects of dopamine replacement; Brain imaging; Dopamine defi ciency; Dopamine overdosing; Dopamine replacement; Parkinson ' s disease

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; ROPINIROLE; DOPAMINE RECEPTOR STIMULATING AGENT;

BODY POSTURE; DISEASE EXACERBATION; DOPAMINE METABOLISM; DOPAMINE REPLACEMENT THERAPY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SUBSTITUTION; DYSKINESIA; DYSTONIA; GLUCOSE UTILIZATION; GOOD CLINICAL PRACTICE; HUMAN; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR BINDING; RESTLESS LEGS SYNDROME; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTITUTION THERAPY; ANIMAL; BRAIN; BRAIN DEPTH STIMULATION; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

ANIMALS; BRAIN; DEEP BRAIN STIMULATION; DOPAMINE; DOPAMINE AGENTS; HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 84868634055     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2012-0037     Document Type: Review

References (319)

1. Abe, K., Uchida, Y., and Notani, M. (2009). Camptocormia in Parkinson's disease. SAGE-Hindawi Access to Research Parkinson's Disease. 2010, ID 267640, 5 pp., DOI: 10.4061/2010/267640.
2. Abecrombie, E.D., Bonatz, A.E., and Zigmond, M.J. (1990). Effects of L-Dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine- treated rats. Brain Res. 525, 36-44. (Pubitemid 20257714)
3. Ahlskog, J.E. (2007). Beating a dead horse: dopamine and Parkinson disease. Neurology 69, 1701-1711. (Pubitemid 350287127)
4. Akpinar, S. (1982). Treatment of restless legs syndrome with levodopa plus benserazide. Letter to the Editor. Arch. Neurol. 39, 739. (Pubitemid 12003440)
5. Albanese, A. (2011). Cell therapy for Parkinson's disease: have the glory days gone? Lancet Neurol. 10, 492-493.
6. Anand, B.K. and Brobeck, J.R. (1951). Hypothalamic control of food intake in rats and cats. Yale J. Biol. Med. 24, 123-140.
7. Angelini, M., Negrotti, A., Marchesi, E., Bonavina, G., and Calzetti, S. (2011). A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: absence of comorbid association. J. Neurol. Sci. 310, 286-288.
8. Antonini, A., Vontobel, P., Psylla, M., Günther, I., Maguire, P.R., Missimer, J., and Leenders, K.L. (1995). Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 52, 1183-1190.
9. Archibald, N.K., Clarke, M.P., Mosimann, U.P., and Burn, D.J. (2009). The retina in Parkinson's disease. Brain 132, 1128-1145.
10. Arnulf, I. (2006). Sleep and wakefulness disturbances in Parkinson's disease. J. Neural. Transm. 70 (Suppl), 357-360. (Pubitemid 44622223)
11. Arnulf, I. and Leu-Semenescu, S. (2009). Sleepiness in Parkinson's disease. Parkinson Relat. Disord. 15, 101-104.
12. Arnulf, I. and Morgan, J. (2011). Not all that goes " bump in the night " is RLS: leg motor restlessness in PD. Neurology 77, 1936-1937.
13. Artemenko, A.R. and Levin, Y.I. (1996). The phototherapy of patients with Parkinsonism. Zh. Neuropatol. Psikhiatr. Im. S.S. Korsakova. 96, 63-66.
14. Arunasmitha, S., Andrade, C., and Pradham, N. (1989). Biphasic effect of apomorphine on rodent motility. Ind. J. Physiol. Pharmacol. 33, 132-133. (Pubitemid 19200423)
15. Asami, T., Kuribara, H., and Tadokoro, S. (1986). Effects of repeated administration of bromocryptine on ambulatory activity in mice, and changes in methamphetamine sensitivity in bromocryptineexperienced mice. Yakubutsu. Seishin. Kodo. 6, 309-317. (Pubitemid 17195425)
16. Asenbaum, S., Brücke, T., Pirker, W., Podreka, I., Angelberger, P., Wenger, S., Wöber, C., Müller, C., and Deecke, L. (1997). Imaging of dopamine transporters with iodine-123- CIT and SPECT in Parkinson's disease. J. Nucl. Med. 38, 1-5.
17. Avital, A., Gross-Isseroff, R., Stryjer, R., Hermesh, H., Weizman, A., and Shiloh, R. (2009). Zolmitriptan compared to propanolol in the treatment of acute neuroleptics-induced akathesia: a comparative double-blind study. Eur. Neuropsychopharmacol. 19, 476-482.
18. Aziz, N.A., van der Marck, M.A., Pijl, H., Olde Rikkert, M.G., Bloem, B.R., and Roos, R.A. (2008). Weight loss in neurodegenerative disorders. J. Neurol. 255, 1872-1880.
19. Badiavas, K., Molyvda, E., Lakovou, I., Tsolaki, M., Psarrokos, K., and Karatzas, N. (2011). SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur. J. Nucl. Med. Mol. Imag. 38, 764-773.
20. Baez, L.A., Ahlskog, J.E., and Randall, P.K. (1977). Body weight and regulatory defi cits following unilateral nigro-striatal lesions. Brain Res. 132, 467-476. (Pubitemid 8166019)
21. Barbeau, A. (1974). The clinical physiology of side effects in longterm L-DOPA therapy. Adv. Neurol. 5, 347-365.
22. Bayard, S., Cochen De Cock, V., and Dauvillers, Y. (2011). Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome. Geriatr. Psychol. Neuropsychiatr. Vieil. 9, 227-235.
23. Bayulkem, K. and Lopez, G. (2010). Nonmotor fl uctuations in Parkinson's disease: clinical spectrum and classifi cations. J. Neurol. Sci. 289, 89-92.
24. Bell, J., Gruenthal, M., Finger, S., and Mangold, R. (1981). Effects of one- and two-stage lesions of the posterior hypothalamus on temperature regulation in the rat. Brain Res. 219, 451-455. (Pubitemid 11087477)
25. Benatru, I., Vaugoyeau, M., and Azulay, J.P. (2008). Postural disorders in Parkinson's disease. Neurophysiol. Clin. 38, 459-465.
26. Benedetti, F., Lanotte, M., Colloca, L., Ducati, A., Zibetti, M., and Lopiano, L. (2009). Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-Parkinsonian placebo response. J. Physiol. 587, 3869-3883.
27. Berg, D. (2008). Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegen. Dis. 5, 133-136. (Pubitemid 351347830)
28. Bernheimer, H. (1964). Distribution of homovanillic acid in the human brain. Nature (Lond.) 204, 587-588.
29. Bernheimer, H. and Hornykiewicz, O. (1965). Herabgroetzte Konzentration der Homovanillinasure im Gehirn von parkinsonkranken Menschen als Ausdruck der St ö rung des sentzalen Dopaminstoffwechaels. Klin. Wachr. 43, 711-715.
30. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973). Brain dopamine and syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455.
31. Birkmayer, W. and Hornykiewicz, O. (1962). Der L-dioxyphenlalanine (=L-dopa) - effect bein Parkinson-syndrom des menschen zur pathogenesese und behandlung der Parkinson-akinese. Neurologie 203, 506-574.
32. Blatt, B. and Lyon, M. (1968). The interrelationship of forebrain and midbrain structures involved in feeding behaviour. Acta Neurol. Scand. 44, 576-595.
33. Bodis-Wollner, I. (1990). The visual system in Parkinson's disease. In: Vision and the Brain, B. Cohen and I. Bodis-Wollner, eds. (New York: Raven Press, Ltd.), pp. 297-314.
34. Bodis-Wollner, I. (2009). Retinopathy in Parkinson's disease. J. Neural. Transm. 116, 1193-1501.
35. Bodis-Wollner, I. and Tzelepi, A. (1998). The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic defi ciency and selective D1 and D2 receptor ligands on the pattern electroretinograms. Vision Res. 38, 1479-1487. (Pubitemid 28240968)
36. Boulamery, A., Simon, N., Vidal, J., and Bruguerolle, B. (2010). Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol. Int. 27, 251-264.
37. Bradbury, A.J., Cannon, J.G., Costall, B., and Naylor, R.J. (1984). A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse. Eur. J. Pharmacol. 105, 33-47. (Pubitemid 14006332)
38. Brooks, D.J. (2010). Imaging dopamine transporters in Parkinson's disease. Biomark. Med. 4, 651-660.
39. Bucci, L. (1974). The biphasic effect of small doses of tranylcypromine on the spontaneous motor activity and learned conditioned behaviour in rats. J. Med. Chem. 18, 437-438.
40. Burke, W.J. (2008). Beating a dead horse: dopamine and Parkinson disease. Neurology 70, 2087.
41. Burunate, E., Castro, R., Diaz-Palarea, M.D., and Rodriguez, M. (1988). Conditioning of the early behavioural response to apomorphine in the rotational model of Parkinson's disease. Eur. J. Pharmacol. 145, 323-327. (Pubitemid 18018853)
42. Calne, D.B., Langston, J.W., Martin, W.R.W., Stoessl, A.J., Ruth, T.J., Adam, M.J., Pate, B.D., and Schulzer, M. (1985). Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317, 246-248. (Pubitemid 16246497)
43. Calne, D.B., Duvoisin, R.C., and Koller, W.C. (1994). Individualizing therapy in patients with disabling Parkinson's disease symptoms. Neurology 44 ( S1 ), 8-11.
44. Carey, R.J. (1982). Unilateral 6-hydroxydopamine lesions of dopamine neurons produce bilateral self-stimulation defi cits. Behav. Brain Res. 6, 101-114. (Pubitemid 12032950)
45. Carlsson, A. (1975). Receptor-mediated control of dopamine metabolism. In: Pre and Post-synaptic Receptors, E. Usdin and W.E. Bunny, eds. (New York: Marcel Dekker), pp. 49-63.
46. Castro, R., Abrev, P., Calzadilla, C.H., and Rodriguez, M. (1985). Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacologia (Berl.) 85, 333-339. (Pubitemid 15123110)
47. Ceravolo, R., Sgado, P., Frosini, D., and Corsini, G.U. (2006). Assessing neuroprotection in Parkinson's disease: from animal models to molecular neuroimaging in vivo. J. Neurol. Transm. 71 (Suppl), 133-141. (Pubitemid 351412115)
48. Ceravolo, R., Frosini, D., Rossi, C., and Bonuccelli, U. (2010). Spectrum of addictions in PD: from DA dysregulation syndrome to impulse control disorders. J. Neurol. 257, S276-S286.
49. Chahine, L.M., Ahmed, A., and Sun, Z. (2011). Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleeprelated measures. Parkinson. Relat. Disord. 17, 208-211.
50. Chen, H., Zhang, S.M., Hemán, M.A., Willett, W.C., and Ascherio, A. (2003). Weight loss in Parkinson's disease. Ann. Neurol. 53, 676-679. (Pubitemid 36529445)
51. Choulli, K., Herman, J.P., Rivet, J.M., Simon, H.R., and Le Moal, M. (1987). Spontaneous and graft-induced behavioural recovery after 6-hydroxydopamine lesions of the nucleus accumbens in the rat. Brain Res. 407, 376-380. (Pubitemid 17085797)
52. Constantinidis, J., Tissot, R., De La Torre, J.C., and Geissbuhler, F. (1969). Essai de localisation des monoamine dans l'hypothalamus humain. Path. Biol. 17, 361-363.
53. Contin, M., Riva, R., Martinelli, P., and Baruzzi, A. (1992). Kineticdynamic relationships of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov. Disord. 7, 244-248.
54. Cooper, B.R., Grant, L.D., and Breese, G.R. (1973). Comparison of the behavioural depressant effects of biogenic amine depleting and neuroleptics agents following various 6-hydroxydopamine treatments. Psychopharmacologia 31, 95-109.
55. Corona, T., Rivera, Nava, C., Reyes, Báez, B., and Carbajal, A. (1991). [Usefulness of drug holiday in patients with Parkinson's disease of more than 5 years of development]. Rev. Invest. Clin. 43, 334-337.
56. Corona, T., Rivera, C., Otero, E., and Stopp, L. (1995). A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease. Clin. Neuropharmacol. 18, 325-332.
57. Dahlström, A. and Fuxe, K. (1964a). A method for the demonstration of monoamine-containing nerve fi bres in the central nervous system. Acta Physiol. Scand. 60, 293-294.
58. Dahlström, A. and Fuxe, K. (1964b). Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 232 (Suppl), 1-55.
59. Darian-Smith, I., Melik, L., Sathian, K., Donnan, G., and Goodwin, A.W. (1985). Movement patterns in monkeys following injection with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a model for Parkinsonism. Neurosci. Lett. 19 (Suppl), 56.
60. Davis, T.L., Brughitta, G., Baronti, F., and Mouradian, M.M. (1991). Acute effects of pulsatile levodopa administration on central dopa-amine pharmacodynamics. Neurology 41, 630-633.
61. Defer, G.L., Widner, H., Marié, R.M., Rémy, P., Levivier, M., and the Conference Participants. (1999). Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov. Disord. 14, 572-584. (Pubitemid 30011449)
62. Delacour, J., Echavarria, M.T., Senault, B., and Houcine, O. (1977). Specifi city of avoidance defi cits produced by 6-hydroxydopamine lesions of the nigro-striatal system of the rat. J. Comp. Physiol. Psychol. 91, 875-885. (Pubitemid 8162739)
63. de la Fuente-Fernández, R. (2004). Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease. Parkinson. Relat. Disord. 10, 125-127. (Pubitemid 38251655)
64. de la Fuente-Fernández, R., Lidstone, S., and Stoessl, A.J. (2006). Placebo effect and dopamine release. J. Neural. Transm. 70 (Suppl), 415-418. (Pubitemid 44622231)
65. De La Torre, J.C. (1972). Catecholamines in the human diencephalon: a histochemical fl uorescence study. Acta Neuropathol. Berl. 21, 165-168.
66. Del Sorbo, F. and Albanese, A. (2008). Levodopa-induced dyskinesias and their management. J. Neurol. 255, 32-41.
67. Di Chiara, G., Porceddu, M.L., Vargiù, L., Argiolas, A., and Gessa, L.L. (1976). Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264, 564-567.
68. Doherty, K.M., van de Warrenburg, B.P., Peralta, M.C., Silveira- Moriyama, L., Azulay, J.P., Gershanik, O.S., and Bloem, B.R. (2011). Postural deformities in Parkinson's disease. Lancet Neurol. 10, 538-549.
69. Donnan, G.A., Woodhouse, D.G., Kaczmarczyk, S.J., Holder, J.E., Paxinos, G., Chilco, P.J., Churchyard, A.J., Kalnins, R.M., Fabinyi, G.A., and Mendelsohn, F.A.O. (1991). Evidence for plasticity of the dopaminergic system in Parkinsonism. Mol. Neurobiol. 5, 421-433.
70. Driver-Dunckley, E., Evidente, V.G., Adler, C.H., Hillman, R., Hernandez, J., Fletcher, G., and Lyons, M.K. (2006). Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov. Disord. 21, 1287-1289. (Pubitemid 44336636)
71. Dubuc, P.U. (1974). Body weight regulation following multistage hypothalamic lesions. Am. J. Physiol. 227, 697-702.
72. Dunnett, S.B. and Rosser, A.E. (2011). Clinical translation of cell transplantation in the brain. Curr. Opin. Organ Transplant. 16, 632-639.
73. Durif, F., Vidailhet, M., Debilly, B., and Agid, Y. (1999). Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov. Disord. 14, 242-245. (Pubitemid 30011840)
74. Editorial (1975). Miracle cures in Parkinson's disease. Br. Med. J. 5974, 1-2.
75. Ehringer, H. and Hornykiewicz, O. (1960). O.: Verteilung von Noradrenalin und Dopamin (3Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr. 38, 1236-1239.
76. Eriksson, T., Magnusson, T., Carlsson, A., Linde, A., and Granérus, A.K. (1984). " On-off " phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma. J. Neural. Transm. 59, 229-240. (Pubitemid 14104013)
77. Eskow Jaunarajs, K.L., Angoa-Perez, M., Kuhn, D.M., and Bishop, C. (2011). Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci. Biobehav. Rev. 35, 556-564.
78. Faglioni, P., Gasparini, M., and Spinnler, H. (1975). [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's translation)]. Riv. Patol. Nerv. Ment. 96, 270-286.
79. Fehér, G., Balás, I., Komoly, S., Dóczi, T., Janszky, J., Aschermann, Z., Balázs, E., Nagy, F., and Kovács, N. (2010). Analysis of antiparkinsonian drug reduction after bilateral subthalmic deep brain stimulation. Ideggyogy Sz. 63, 314-319.
80. Fehling, C. (1966). Treatment of Parkinson's syndrome with L-Dopa a double blind study. Acta Neurol. Scand. 42, 367-372.
81. Fibiger, H.C., Zis, A.P., and McGeer, E.G. (1973). Feeding and drinking defi cits after 6-hydroxydopamine administration in the rat: similarities to the lateral hypothalamic syndrome. Brain Res. 55, 135-148.
82. Finger, S. and Almli, C.R. (1985). Brain damage and neuroplasticity: mechanisms of recovery or development? Brain Res. 357, 177-186. (Pubitemid 16160407)
83. Finger, S., Walbran, B., and Donald, G.S. (1973). Brain damage and behavioral recovery: serial lesion phenomena. Brain Res. 63, 1-18.
84. Fink, J.S. and Smith, G.P. (1979). L-dopa repairs defi cits in locomotor investigatory exploration produced by denervation of catecholamine terminal fi elds in the forebrain of rats. J. Comp. Phys. Psych. 93, 66-73. (Pubitemid 9140563)
85. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719. (Pubitemid 32204988)
86. Friedhoff, A.J., Hekimian, L., Alpert, M., and Tobach, E. (1963). Dihydroxyphenylalanine in extrapyramidal disease. J. Am. Med. Assoc. 184, 285-286.
87. Fujimoto, K. (2006). Dropped head in Parkinson's disease. J. Neurol. 253, V1121-V1126.
88. Fuxe, K. (1964). Cellular localization of monoamines in the median eminence and the infundibular stem of some mammals. Z. Zellforsch. Mikrosk. Anat. 61, 710-724.
89. Gaddy, J.R. and Neill, D.B. (1977). Differential behavioural changes following intrastriatal application of 6-hydroxydopamine. Brain Res. 119, 439-446. (Pubitemid 8006258)
90. Gamboa, J., Jiménez-Jiménez, F.J., Mate, M.A., and Cobeta, I. (2001). [Voice disorders caused by neurological diseases]. Rev. Neurol. 33, 153-168. (Pubitemid 32885052)
91. Gillingham, F.J. (1975). Miracle cures in Parkinson's disease. Br. Med. J. 3, 303.
92. Gisselmann, A., Boudry, C., Marin, A., and Ballivet, J. (1976). Clinical and biochemical considerations on depressive states occurring during Parkinsonian syndrome treated by L-Dopa. Encephale 2, 105-113.
93. Gjerstad, M.D., Tysnes, O.B., and Larsen, J.P. (2011). Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 77, 1941-1946.
94. Glick, S.D., Greenstein, S., and Zimmerberg, B. (1972). Facilitation of recovery by a -methyl- p -tyrosine after lateral hypothalamic damage. Science 177, 534-535.
95. Goetz, C.G., Wuu, J., McDermott, M.P., Adler, C.H., Fahn, S., Freed, C.R., Hauser, R.A., Olanow, W.C., Shoulson, I., Tandon, P.K., Leurgans, S. and Parkinson Study Group. (2008). Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23, 690-699.
96. Grandas, F. and Obeso, J.A. (1989). Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin. Neuropharmacol. 12, 14-22. (Pubitemid 19058129)
97. Gross, R.E., Watts, R.L., Hauser, R.A., Bakay, R.A., Reichmann, H., von-Kummer, R., Ondo, W.G., Reissig, E., Eisner, W., Steiner- Schulze, H., et al., Spheramine Investigational Group. (2011). Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 10, 509-519.
98. Hagell, P., Piccini, P., Bjöklund, A., Brundin, P., Rehncrona, S., Widner, H., Crabb, L., Pavese, N., Oertel, W.H., Quinn, N., et al. (2002). Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5, 627-628. (Pubitemid 34742975)
99. Halliwell, B. (2001). Role of free radicals in the neurodegenerative disease: therapeutic implications for antioxidant treatment. Drugs Aging 18, 685-716. (Pubitemid 32948277)
100. Hantraye, P., Varastet, M., Peschanski, M., Riche, D., Cesaro, P., Willer, J.C., and Maziere, M. (1993) Stable Parkinsonian syndrome and uneven loss of striatal dopamine fi bres following chronic MPTP administration in baboons. Neuroscience 53, 169-178. (Pubitemid 23083318)
101. Harnois, C. and Di Paolo, T. (1990). Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 31, 2473-2475.
102. Hattori, S., Naoi, M., and Nishino, H. (1994). Striatal dopamine turnover during treadmill running in the rat: relation to the speed of running. Brain Res. Bull. 35, 41-49. (Pubitemid 24230646)
103. Hauser, R.A. and Holford, N.H.G. (2002). Quantitative description of loss of clinical benefi t following withdrawal of levodopacarbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 17, 961-968. (Pubitemid 36041001)
104. Hauser, R.A., Freeman, T.B., Snow, B.J., Nauert, M., Gauger, L., Kordower, J.H., and Olanow, W. (1999). Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56, 179-187. (Pubitemid 29076182)
105. Hefti, F., Melamed, E., and Wurtman, R.J. (1980). Partial lesions of the dopaminergic nigro-striatal system in rat brain: biochemical characterization. Brain Res. 195, 123-137. (Pubitemid 10077835)
106. Heimer, G., Rivlin-Etzion, M., Bar-Gad, I., Goldberg, J.A., Haber, S.N., and Bergman, H. (2006). Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra- hydropyridine primate model of Parkinsonism. J. Neurosci. 26, 8101-8114. (Pubitemid 44315135)
107. Henchcliffe, C. and Severt, W.L. (2011). Disease modifi cation in Parkinson's disease. Drugs Ageing 28, 605-615.
108. Hensman, D.J. and Bain, P.G. (2006). Levodopa can worsen tremor associated with dystonia. Mov. Disord. 21, 1778-1780. (Pubitemid 44742221)
109. Hetherington, A.W. and Ranson, S.W. (1940). Hypothalamic lesions and adiposity in the rat. Anat. Rec. 78, 149-172.
110. Ho, B., Prakash, R., Morgan, J.C., and Sethi, K.D. (2007). A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease. Nat. Clin. Pract. Neurol. 3, 526-530. (Pubitemid 47377612)
111. Hodge, G.K. and Butcher, L.L. (1979). Role of the pars compacta of the substantia nigra in circling behaviour. Pharmacol. Biochem. Behav. 10, 695-709. (Pubitemid 9215085)
112. Hodge, G.K. and Butcher, L.L. (1980). Pars compacta of the substantia nigra modulates motor activity but is not involved importantly in regulating food and water intake. Naunyn-Schmiedeberg's Arch. Pharmacol. 313, 51-67. (Pubitemid 10043253)
113. Hökfelt, T. and Ungerstedt, U. (1973). Specifi city of 6-hydroxydopamine induced degeneration of central monoamine neurones: electron and fl uorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system. Brain Res. 60, 269-297.
114. Holford, N. and Nutt, J.G. (2008). Disease progression, drug action and Parkinson's disease: why time cannot be ignored. Eur. J. Clin. Pharmacol. 64, 207-216.
115. Hollingworth, S.A., Rush, A., Hall, W.D., and Eadie, M.J. (2011). Utilization of anti-Parkinson drugs in Australia: 1995-2009. Pharmacolepidemiol. Drug Saf. 20, 450-456.
116. Horiuchi, M., Uehara, K., Komo, T., Sugihara, H., and Takahashi, Y. (2001). A case of elderly onset Parkinson's disease complicated by dropped head syndrome. Nihon. Ronen. Igakkai. Zasshi. 38, 693-695.
117. Hornykiewicz, O. (1963). Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der substantia nigra des normalen und Parkinsonkranken Mensechen. Wien. lkin. Wachre. 75, 309-312.
118. Hornykiewicz, O. (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964.
119. Huang, Y.M. and Yin, Z.Q. (2011). Minor retinal degeneration in Parkinson's disease. Med. Hypoth. 76, 194-196.
120. Hughes, A.J., Lees, A.J., and Stern, G.M. (1991). The motor response to sequential apomorphine in Parkinsonian fl uctuations. J. Neurosurg. Psychiatry 54, 350-360.
121. Hynes, M.D., Anderson, C.D., and Lal, H. (1971). Aphagia and adipsia after nigro-striatal bundle (NSB) lesions: facilitation of recovery by blockade of central dopaminergic receptors. Psychopharmacology 15, 218-223.
122. Iida, M., Miyazaki, I., and Tanaka, K. (1999). Dopamine D2 receptor- mediated antioxidant and neuroprotective effects of ropinerole, a dopamine agonist. Brain Res. 838, 51-59. (Pubitemid 29389818)
123. Ilgin, N. (1998). Functional imaging of neurotransmitter systems in movement disorders. Q. J. Nucl. Med. 42, 179-192. (Pubitemid 28529871)
124. Issidorides, M.R. (1971). Neuronal vascular relationships in the zona compacta of normal and Parkinsonian substantia nigra. Brain Res. 25, 289-299.
125. Jackson, J.H. (1887). Remarks on evolution and dissolution of the nervous system. J. Ment. Sci. 33, 25-48.
126. Jackson, J.H. (1928). On the anatomical and physiological localisation of movement in the brain. In: Selected Writing of J.H. Jackson, J. Taylor, ed. (London: Hodder and Stoughton Press), pp. 1931-1932.
127. Jankovic, J. (2010). Camptocormia, head drop and other bent spine syndromes: heterogeneous aetiology and pathogenesis of Parkinsonian deformities. Mov. Disord. 15, 527-528.
128. Kaplan, H.I. and Sadock, B.J. (1981). Modern Synopsis of Comprehensive Textbook of Psychiatry III, 3rd edition (London: Williams and Wilkins Baltimore).
129. Kashihara, K. (2006). Weight loss in Parkinson's disease. J. Neurol. 253, 38-41.
130. Kashihara, K., Ohno, M., and Tomita, S. (2006). Dropped head syndrome in Parkinson's disease. Mov. Disord. 21, 1213-1216. (Pubitemid 44336610)
131. Kastrup, A., Gdynia, H.J., Nägele, T., and Riecker, A. (2008). Dropped-head syndrome due to steroid responsive focal myosotis: a case report and review of the literature. J. Neurol. Sci. 267, 162-165. (Pubitemid 351248906)
132. Kataoka, H. and Ueno, S. (2011). Dropped head associated with amantadine in Parkinson disease. Clin. Neuropharmacol. 34, 48-49.
133. Kedia, S., Moro, E., Tagliati, M., Lang, A.E., and Kumar, R. (2004). Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 63, 2410-2412. (Pubitemid 40024365)
134. Kelly, P.H., Seviour, P.W., and Iversen, S.D. (1975). Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94, 507-522.
135. Kelly, E., Jenner, P., and Marsden, C.D. (1987). Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylactic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats. J. Pharm. Pharmacol. 39, 196-202. (Pubitemid 17033350)
136. Kelly, E.F., Kelly, E.W., Crabtree, A., Gauld, A., Grosso, M., and Greyson, B. (2010). Irreducible Mind. Toward a Psychology for the 21 st century (Toronto: Rowman & Littlefi eld Publishers, Inc.).
137. Kilpatrick, I.C., Starr, M.S., and Summerhayes, M. (1985). Brain activity following intranigral or intrathalamic drug injections in the rat. Brain Res. 94, 533-561.
138. Kim, H.J., Oh, E.S., Lee, J.H., Moon, J.S., Oh, J.E., Shin, J.W., Lee, K.J., Baek, I.C., Jeong, S.H., Song, H.J., et al. (2011). Relationship between changes of body mass index (BMI) and cognitive decline in Parkinson's disease (PD). Arch. Gerontol. Geriatr. Epub ahead of print. July 13, 2011.
139. Kirsch, I. (2010). The emperor's new drugs: exploding the antidepressant myth. (New York: Basic Books).
140. Kolb, B. (1977). Studies on the caudate-putamen and the dorsomedial thalamic nucleus of the rat: implications for mammalian frontal-lobe function. Physiol. Behav. 18, 237-244. (Pubitemid 8083653)
141. Koob, G.F., Riley, S.J., Smith, S.C., and Robbins, T.W. (1978) Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity and amphetamine anorexia in the rat. J. Comp. Physiol. Psychol. 92, 917-927. (Pubitemid 9036050)
142. Koziorowski, D. and Friedman, A. (2007). Levodopa " drug holiday " with amantadine infusions as a treatment of complications in Parkinson's disease. Mov. Disord. 22, 1033-1036. (Pubitemid 47007619)
143. Kozlowski, M.R. and Marshall, J.F. (1980). Plasticity of 14 C-2-deoxy D-glucose incorporation into neostriatum and related structures in response to dopamine neurone damage and apomorphine replacement. Brain Res. 197, 167-183. (Pubitemid 10036871)
144. Kozlowski, M.R. and Marshall, J.F. (1983). Recovery of function and basal ganglia 14 C-2-deoxyglucose uptake after nigro-striatal injury. Brain Res. 259, 237-248. (Pubitemid 13176127)
145. Krausz, Y., Bonne, O., Marciano, R., Yaffe, S., Lerer, B., and Chisin, R. (1996). Brain SPECT imaging of neuropsychiatric disorders. Eur. J. Radiol. 21, 183-187. (Pubitemid 26096598)
146. Kumar, S., Bhatia, M., and Behari, M. (2002). Sleep disorders in Parkinson's disease. Mov. Disord. 17, 775-781. (Pubitemid 41295024)
147. Kummer, A., Cardoso, F., and Teixeira, A.L. (2010). Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease. Arg. Neuropsiquiatr. 68, 495-501.
148. Kurlan, R., Richard, I.H., and Deeley, C. (2006). Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J. Gen. Intern. Med. 21, C1-C4. (Pubitemid 44665324)
149. Kuypers, H.G. (1974). Functional recovery after lesions of the nervous system. IV. Structural correlates of recovery in adult subjects. Recovery of motor function in rhesus monkeys. Neurosci. Res. Prog. Bull. 12, 240-244.
150. Lampreia, T., Bugalho, P., Soares, P., and Santos, L. (2011). Delayedonset Parkinsonian tremor following a mesencephalic lesion. Parkinsonism Relat. Disord. 17, 65-66.
151. Lane, E.L., Björklund, A., Dunnett, S.B., and Winkler, C. (2010). Neural grafting in Parkinson's disease unravelling the mechanisms underlying graft-induced dyskinesia. Prog. Brain Res. 184, 295-309.
152. Lang, A.E. (1987). Restless legs syndrome and Parkinson's disease: insights into pathophysiology. Clin. Neuropharmacol. 10, 476-478. (Pubitemid 17141074)
153. Lang, A.E. and Johnson, K. (1987). Akathisia in idiopathic Parkinson's disease. Neurology 37, 477-481. (Pubitemid 17031748)
154. Langston, J.W. (1985). I. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci. 36, 201-206 (Pubitemid 15193978)
155. Langston, J.W., Widner, H., Goetz, C.G., Brooks, D., Fahn, S., Freeman, T., and Watts, R. (CAPIT Committee) (1992). Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov. Disord. 7, 2-13.
156. Lanotte, M., Lopiano, L., Torre, E., Bergamasco, B., Collaca, L., and Benedetti, F. (2005). Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region. Brain Behav. Immun. 19, 500-509. (Pubitemid 41407698)
157. Lava, N.S. and Factor, S.A. (2001). Focal myopathy as a cause of antecollis in Parkinsonism. Mov. Disord. 16, 754-756. (Pubitemid 36040860)
158. Lavy, S., Melamed, E., Cooper, G., and Bentin, S. (1979). Regional cerebral blood fl ow in patients with Parkinson's disease. Arch. Neurol. 36, 344-348. (Pubitemid 9150279)
159. Lee, L.A., Slater, P., and Crossman, A.R. (1981). The role of the substantia nigra in a striatally-evoked motor response in the rat: effects of intranigral drugs and lesions. Neuroscience 6, 359-366. (Pubitemid 11152465)
160. Leibowitz, S.F. and Rossakis, C. (1979a). L-Dopa feeding suppression: effect on catecholamine neurons of the perifornical lateral hypothalamus. Psychopharmacology (Berl.) 61, 273-280. (Pubitemid 9227019)
161. Leibowitz, S.F. and Rossakis, C. (1979b). Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat. Brain Res. 172, 115-130. (Pubitemid 10200583)
162. Leibowitz, S.F., Hammer, N.J., and Chang, K. (1983). Feeding behavior induced by central norepinephrine injection is attenuated by discrete lesions in the hypothalamic paraventricular nucleus. Pharmacol. Biochem. Behav. 19, 945-950. (Pubitemid 14209517)
163. Leonard, L. (1977). Food and water intake after bilateral caudate and putamen lesions in rats. Acta Physiol. Acad. Sci. Hung. 50, 27-34.
164. Lesser, R.P., Fahn, S., Snider, S.R., Cote, L.J., Isgreen, W.P., and Barrett, R.E. (1979). Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29, 1253-1260. (Pubitemid 9231590)
165. Lewitt, P.A., Dubow, J., and Singer, C. (2011). Is levodopa toxic? Insights from a brain bank. Neurology 77, 1414-1415.
166. Lidstone, S.C., Schulzer, M., Dinelle, K., Mak, E., Sossi, V., Ruth, T.J., de la Fuente-Fernández, R., Phillips, A.G., and Stoessl, A.J. (2010). Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 67, 857-865.
167. Lim, A., Leow, L., Huckabee, M.L., Frampton, C., and Anderson, T. (2008). A pilot study of respiration and swallowing integration in Parkinson's disease: " on " and " off " levodopa. Dysphagia 23, 76-81. (Pubitemid 351207628)
168. Lindvall, O. and Björklund, A. (2011). Cell therapeutics in Parkinson's disease. Neurotherapeutics 8, 539-548.
169. Ljungberg, T. and Ungerstedt, U. (1976). Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats. Physiol. Behav. 16, 277-283.
170. Louis, E.D., Winfield, L., Fahn, S., and Ford, B. (2001). Speech dysfl uency exacerbated by levodopa in Parkinson's disease. Mov. Disord. 16, 562-565.
171. Lyons, M.K. (2011). Deep brain stimulation: current and future clinical applications. Mayo Clin. Proc. 86, 662-672.
172. 123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57, 2089-2094. (Pubitemid 33126879)
173. Marks, W.J. Jr., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Sacy, M., Turner, D., Verhagen, L., et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind randomised, controlled trial. Lancet Neurol. 9, 1164-1172.
174. Marsden, C.D. (1980). " On-off " phenomena in Parkinson's disease. In: Parkinson's Disease: Current Progress, Problems and Management, U.K. Rinne, M. Klinger and G. Stamm, eds. (Amsterdam: Elsevier), pp. 241-254.
175. Marsden, C.D. and Jenner, P. (1980). The pathophysiology of extrapyramidal side-effects of neuroleptics drugs. Psychol. Med. 10, 55-72. (Pubitemid 11141134)
176. Marsh, G.G. and Markham, C.H. (1973). Does levodopa alter depression and psychopathology in Parkinsonism patients? J. Neurol. Neurosurg. Psychiatry 36, 925-935.
177. Marshall, J.R. and Teitelbaum, P. (1973). A comparison of the eating in response to hypothermic and glucoprivic challenges after nigral 6-hydroxydopamine and lateral hypothalamic electrolytic lesions in rats. Brain Res. 55, 229-233.
178. Marshall, J.R., Richardson, J.S., and Teitelbaum, P. (1974). Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J. Comp. Physiol. Psychol. 87, 808-830.
179. Martin, W.R. and Hayden, M.R. (1987). Cerebral glucose and dopa metabolism in movement disorders. Can. J. Neurol. Sci. 14, 448-451. (Pubitemid 17147631)
180. Martinez, F., Castillo, J., Castro, A., Lema, M., and Noya, M. (1992). [The results of drug holiday in Parkinson's disease]. Neurologia 7, 254-259.
181. Mason, S. (1981). Animal models of Huntington's chorea. Trends. Neurosci. Oct. x.
182. Mason, G., Mestre, D., and Blin, O. (1993). Dopaminergic modulation of visual sensitivity in man. Fund. Clin. Pharmacol. 7, 449-463. (Pubitemid 23313596)
183. Maxxiotta, J.C., Phelps, M.E., Plummer, D., and Kuhl, D.E. (1981). Quantitation in positron emission computed tomography: physical anatomical effects. J. Comp. Assist. Tomogr. 5, 734-743. (Pubitemid 11004749)
184. McGeer, P.L., Boulding, J.E., Gibson, W.C., and Foulkes, F.G. (1961). Drug-induced extrapyramidal reactions. J. Am. Med. Assoc. 177, 665-670.
185. Meara, J., Bhowmick, B.K., and Hobson, P. (1999). Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 28, 99-102. (Pubitemid 29161211)
186. Meeusen, R., Smolders, I., Sarre, S., de Meirleir, K., Keizer, H., Serneels, M., Ebinger, G., and Michotte, Y. (1997). Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study. Acta Physiol. Scand. 159, 335-341. (Pubitemid 27193342)
187. Melamed, E., Lavy, S., Cooper, G., and Bentin, S. (1978). Regional cerebral blood fl ow in Parkinsonism. J. Neurol. Sci. 38, 391-397.
188. Mendels, J., Stinnett, J.L., Burns, D., and Frazer, A. (1975). Amine precursors and depression. Arch. Gen. Psychiatry 32, 22-30.
189. Mendez, I., Sanchez-Pernaute, R., Cooper, O., Vin̂eula, A., Ferrari, D., Björklund, L., Dagher, A., and Isacson, O. (2005). Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128, 1498-1510. (Pubitemid 41373670)
190. Mercado, R., Constanantoyannis, C., Mandat, T., Kumar, A., Schulzer, M., Stoessl, A.J., and Honey, C.R. (2006). Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov. Disord. 21, 1457-1461. (Pubitemid 44613300)
191. Meng, T., Zheng, Z.H., Liu, T-T., and Lin, L. (2012). Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat. Neurochem. Res. 37, 1050-1056.
192. Messiha, F.S. (1989). Mouse strain-dependent effect of amantadine on motility and brain biogenic amines. Arch. Int. Pharmacodyn. Ther. 302, 74-85. (Pubitemid 20210265)
193. Mindham, R.H.S., Marsden, C.D., and Parkes, J.D. (1976). Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol. Med. 6, 23-33.
194. Minguez-Castellanos, A., Escamilla-Sevilla, F., Katati, M.J., Martin- Linares, J.M., Meermans, M., Ortega-Moreno, A., and Arjona, V. (2005). Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J. Neurol. Neurosurg. Psychiatry 76, 34-39. (Pubitemid 40013488)
195. Miwa, H. (2007). Placebo effect in Parkinson's disease. Brain Nerve 59, 139-146.
196. Miyoshi, K., Ueki, A., and Nagano, O. (1996). Management of psychiatric symptoms of Parkinson's disease. Eur. Neurol. 36, 49-58.
197. Morizane, A., Li, J.-Y., and Brundin, P. (2008). From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tiss. Res. 331, 323-336. (Pubitemid 50004907)
198. Moro, E., Scerrati, M., Romito, L.M., Roselli, R., Tonali, P., and Albanese, A. (1999). Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53, 85-90. (Pubitemid 29329653)
199. Moro, E., Lozano, A.M., Pollak, P., Agid, Y., Rehncrona, S., Volkmann, J., Kulisevsky, J., Obeso, J.A., Albanese, A., Hariz, M.I., et al. (2010). Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov. Disord. 25, 578-586.
200. Morrish, P.K., Sawle, G.V., and Brooks, D.J. (1995). Clinical and [ 18 F]dopa PET fi ndings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59, 597-600.
201. Morrish, P.K., Rakshi, J.S., Bailey, D.L., Sawle, G.V., and Brooks, D.J. (1998). Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [ 18 F]dopa PET. J. Neurol. Neurosurg. Psychiatry 64, 314-319.
202. Müller, C.P. and Huston, J.P. (2007). Dopamine activity in the occipital and temporal cortices of rats: dissociating effects of sensory but not pharmacological stimulation. Synapse 61, 254-258.
203. Müller, T., Woitalla, D., Saft, C., and Kuhn, W. (2000). Levodopa in plasma correlates with body weight of Parkinsonian patients. Parkinsonism Relat. Disord. 6, 171-173. (Pubitemid 30246071)
204. Müller, C.P., De Souza Silva, M.A., and Huston, J.P. (2007). Double dissociating effects of sensory stimulation and cocaine on serotonin activity in the occipital and temporal cortices. Neuropharmacology 52, 854-862. (Pubitemid 46227476)
205. Myers, F.W.H. (1895). Resolute credulity. Proc. Soc. Psychol. Res. 11, 213-234.
206. Neff, N.H. and Hadjiconstantinou, M. (1995). Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Prog. Brain Res. 106, 91-97. (Pubitemid 26022910)
207. Neill, D.B. and Linn, C.L. (1975). Defi cits in consummatory responses to regulatory challenges following basal ganglion lesions in rats. Physiol. Behav. 14, 617-624.
208. Nikolaus, S., Larisch, R., Vosberg, H., Beu, M., Hautzel, H., Wirrwar, A., Mueller, H.-W., and Antke, C. (2011). In vivo imaging neurotransmitter function. Nuklearmedizin 4, 155-166.
209. Nuovo, J. (2011). The impact of a drug safety warning on discussions between doctors and their patients; the case of rosiglitazone. Pharmacol. Pharm. 2, 168-172.
210. Nutt, J.G. (2007). Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov. Disord. 22, 1-9. (Pubitemid 46382666)
211. Nutt, J.G., Woodward, W.R., Hammerstad, J.P., Carter, J.H., and Anderson, J.L. (1984) The " on-off " phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310, 483-488. (Pubitemid 14189988)
212. Nutt, J.G., Gancher, S.T., and Woodward, W.R. (1988). Does an inhibitory action of levodopa contribute to motor fl uctuations? Neurology 38, 1553-1557.
213. Öberg, R.G.E. and Divac, I. (1981) The basal ganglia and the control of movement. Levels of motor planning. Cognition and the control of movement. Trends Neurosci. 4, 122-124.
214. Ogawa, N. (1994). Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur. Neurol. 34 (Suppl 3), 20-28. (Pubitemid 24294542)
215. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, J., and Freeman, T.B. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414. (Pubitemid 37072046)
216. Olson, L., Nyström, B., and Seiger, Å. (1973). Monoamine fl uorescence histochemistry of human post mortem brain. Brain Res. 63, 231-247.
217. Oltmans, G.A. and Harvey, J.A. (1972). LH syndrome and brain catecholamine levels after lesions of the nigro-striatal bundle. Physiol. Behav. 8, 69-78.
218. Paalzow, G.H.M. and Paalzow, L.K. (1986). L-Dopa: how it may exacerbate Parkinsonian symptoms. Trends Pharmacol. Sci. 7, 15-19. (Pubitemid 16079185)
219. Pahwa, R., Lyons, K.E., Wilkinson, S.B., Simpson, R.K. Jr., Ondo, W.G., Tarsy, D., Norregaard, T., Hubble, J.P., Smith, D.A., Hauser, R.A., et al. (2006). Long-term evaluation of deep brain stimulation of the thalamus. J. Neurosurg. 104, 506-512.
220. Palacios, J.M., Chinaglia, G., and Probst, A. (1989). Visualizing receptors for neurotransmitters in the human brain with autoradiography. Neurosurg. Rev. 12, 11-20. (Pubitemid 19144233)
221. Parkinson Study Group. (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287, 1653-1661.
222. Parush, N., Tishby, N., and Bergman, H. (2011). Dopaminergic balance between reward maximization and policy complexity. Front. Syst. Neurosci. 5, 22.
223. Paus, S., Schmitz-Hübsch, T., Wullner, U., Vogel, A., Klockgether, T., and Abele, M. (2007). Bright light therapy in Parkinson's disease: a pilot study. Mov. Disord. 22, 1495-1498. (Pubitemid 47280641)
224. Peterson, D. (1980). Is your brain really necessary? World Med. 15, 21-24.
225. Physician's Desk Reference (2010). PDR Network. LLC, Montvale, NJ, USA.
226. Pilf, C., Schingnitz, G., and Hornykiewicz, O. (1991). Effect of 1-methyl-4-phenyl-1,2,3,5-tetrahydopyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605.
227. Pojda, S.M. and Brus, R. (1976). The effect of central chemical sympathectomy on the oxygen uptake; anaerobic glycolysis and lactic acid dehydrogenase activity in the retina of white rats. Albrecht von Graef Arch. Klin. Exp. Ophthalmol. 200, 223-226.
228. Pollo, A., Torre, E., Lopiano, L., Rizzone, M., Lanotte, M., Cavanna, A., Bergamasco, B., and Benedetti, F. (2002). Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13, 1383-1386.
229. Powley, T.L. and Keesey, R.E. (1970). Relationship of body weight to the lateral hypothalamic feeding syndrome. J. Comp. Physiol. Psychol. 70, 25-36.
230. Price, M.J., Feldman, R.G., Adelberg, D., and Kayne, H. (1992). Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 42, 887-890.
231. Pum, M.E., Huston, J.P., De Souza Silva, M.A., and Müller, C.P. (2008). Visual sensory-motor gating by serotonin activation in the medial prefrontal and occipital, but not in the rhinal, cortices in rats. Neuroscience 153, 361-372.
232. Pum, M.E., Huston, J.P., Müller, C.P., and De Souza Silva, M.A. (2009). Light-induced activity in the activity box is not aversively motivated and does not show between-trial habituation. Physiol. Behav. 96, 434-439.
233. Reichel, G., Kirchhöfer, U., and Stenner, A. (2001). Camptocormiasegmental dystonia. Proposal of a new defi nition for an old disease. Nervenarzt 72, 281-285. (Pubitemid 32288971)
234. Rice, J.E., Antic, R., and Thompson, P.D. (2002). Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 17, 524-527. (Pubitemid 36040966)
235. Richards, J.B., Sabol, K., and Freed, C.R. (1990). Unilateral dopamine depletion causes bilateral defi cits in conditioned rotation in rats. Pharmacol. Biochem. Behav. 36, 217-233.
236. Rieu, I., Derost, P., Ulla, M., Marques, A., Debilly, B., De Chazeron, I., Chéreau, I., Lemaire, J.J., Boirie, Y., Llorca, P.M., et al. (2011). Body weight gain and deep brain stimulation. J. Neurol. Sci. 310, 267-270.
237. Riley, D.E. and Lang, A.E. (1993). The spectrum of levodopa-related fl uctuations in Parkinson's disease. Neurology 43, 1459-1464. (Pubitemid 23230524)
238. Rinne, U.K. (1978). Recent advances in research of Parkinsonism. Acta Neurol. Scand. 57, 77-113.
239. Rodnitzky, R.L. (1998) Visual dysfunction in Parkinson's disease. Clin. Neurosci. 5, 102-106. (Pubitemid 128751585)
240. Romito, L.M. and Albanese, A. (2010). Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J. Neurol. 257, S298-S304.
241. Rothwell, J.C. (2011). The motor functions of the basal ganglia. J. Integr. Neurosci. 10, 303-315.
242. Rougemont, D., Baron, J.C., Collard, P., Bustany, P., Comar, D., and Agid, Y. (1984). Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 47, 824-830. (Pubitemid 14059374)
243. Sachdev, P. and Longragan, C. (1991). The present status of akathesia. J. Nerv. Ment. Dis. 179, 381-391.
244. Sagar, J.M. and Snodgrass, S.R. (1980). Effects of substantia nigra lesions of forebrain 2-deoxyglucose retention in the rat. Brain Res. 185, 335-348.
245. Savica, R., Kumar, N., Ahlskog, J.E., Josephs, K.A., Matsumoto, J.Y., and McKeon, A. (2011). Parkinsonism and dropped head: dystonia, myopathy or both? Parkinson. Relat. Disord. 18, 30-34.
246. Schapira, A.H. and Jenner, P. (2011). Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 26, 1049-1055.
247. Schiff, B.B. and Carter, D. (1977). Long-term effects of caudate nucleus lesions on body weight in the rat. Physiol. Behav. 18, 375-379. (Pubitemid 8108653)
248. Schneider, J.S. (1990). Chronic exposure to low doses of MPTP: II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 534, 25-36.
249. Schneider, J.S., Yowiler, A., and Markham, C.H. (1987). Selective loss of sub-populations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411, 144-150. (Pubitemid 17084779)
250. Schultze, M.J. (1971). Functional differences of serial versus simultaneous lesions of the rat caudate nucleus. In: Proc. East. Psychol. Assoc. NYC, April 15-17. pp. 61.
251. Schwartz, W.J. (1978). A role for the dopaminergic nigro-striatal bundle in the pathogenesis of altered brain glucose consumption after lateral hypothalamic lesion. Evidence using the 14 C-labeled deoxyglucose technique. Brain Res. 158, 129-147. (Pubitemid 9059992)
252. Seibyl, J.P., Marek, K.L., Quinlan, D., Sheff, K., Zoghbi, S., Yea- Ponce, Y., Baldwin, M., Fussell, B., Smith, O., Charney, D.S., et al. (1995). Decreased single-photon emission computed tomographic [ 123 I] CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589-598.
253. Sethi, K. (2008). Levodopa unresponsive symptoms in Parkinson disease. Mov. Disord. 23, S521-S533.
254. Sharma, J.C., Macnamara, L., Hasoon, M., Vassallo, M., and Ross, I. (2006). Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinson. Relat. Disord. 12, 499-505. (Pubitemid 44793116)
255. Sharma, J.C., Bachmann, C.G., and Linazasoro, G. (2010). Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 16, 490-497.
256. Shon, Y.M., Lee, K.H., Goerss, S.J., Kim, I.Y., Kimble, C., Van Gompel, J.J., Bennet, K., Blaha, C.D., and Chang, S.Y. (2010). High frequency stimulation of the subthalamic nucleus evokes striatal dopamine release in a large animal model of human DBS neurosurgery. Neurosci. Lett. 475, 136-140.
257. Shoulson, I., Glaubiger, G.A., and Chase, T.N. (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinsonian patients. Neurology 25, 1144-1148.
258. Siegert, S., Hazan, D., and Szyper-Kravitz, M. (2011). Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment. Isr. Med. Assoc. J. 13, 189-190.
259. Simmonds, M.A. and Uretsky, N.J. (1970). Central effects of 6-hydroxydopamine on the body temperature of the rat. Br. J. Pharmacol. 40, 630-638.
260. Sindhu, K.M., Saravanan, K.S., and Mohanakumar, K.P. (2005). Behavioral differences in a rotenone-induced hemi-Parkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res. 1051, 25-34. (Pubitemid 40982623)
261. Singer, G. and Willis, G.L. (1977). The pharmacological basis for the lateral hypothalamic syndrome. Brain Res. Bull. 2, 485-489. (Pubitemid 8265131)
262. Silva, M.G., Boyle, M.A., Finger, S., Numan, B., Bouzrara, A.A., and Almli, C.R. (1986). Behavioral effects of large and small lesions of the rat medial frontal cortex. Exp. Brain Res. 65, 176-181.
263. Smith, C.B. and Dews, P.B. (1962). Antagonism of locomotor suppressant effects of reserpine in mice. Psychopharmacologia 3, 55-59.
264. Smith, A.D., Amalric, M., Koob, G.F., and Zigmond, M.J. (2002). Effect of bilateral 6-hydroxydopamine lesions of the medial forebrain bundle on reaction time. Neuropsychopharmacology 26, 756-764. (Pubitemid 34455028)
265. Smith, Y., Wichmann, T., Factor, S.A., and Delong, M.R. (2011). Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37, 213-246.
266. Solla, P., Cannas, A., Marrosu, F., and Marrosu, M.G. (2010). Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®). Neuropsychiatr. Dis. Treat. 6, 483-490.
267. Song, I.U., Kim, J.S., and Lee, K.S. (2008). Dopa-responsive camptocormia in a patient with multiple system atrophy. Parkinsonism Relat. Disord. 14, 161-163. (Pubitemid 351726300)
268. Spencer, J.P., Jenner, A., Butler, J., Aruoma, O.I., Dexter, D.T., Jenner, P., and Halliwell, B. (1996). Evaluation of the pro-oxidant and antioxidant actions of L-Dopa and dopamine in vitro: implications for Parkinson's disease. Free Rad. Res. 24, 95-105. (Pubitemid 26035630)
269. Stacy, M. (2000). Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 20, 8s - 10s.
270. Stahle, L. and Ungerstedt, U. (1987). On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behavior in rats. Psychopharmacology 91, 139-146. (Pubitemid 17002264)
271. Stiasny-Kolster, K., Kohnen, R., Möller, J.C., Trenkwalder, C., and Oertel, W.H. (2006). Validation of the " L-DOPA test " for diagnosis of restless legs syndrome. Mov. Disord. 21, 1333-1339. (Pubitemid 44613281)
272. Stice, E., Yokum, S., Blum, K., and Bohon, C. (2010). Weight gain is associated with reduced striatal response to palatable food. J. Neurosci. 30, 13105-13109.
273. Stoller, W.L. (1974). Food, water and saccharine solution intake in rats with posterior striatal lesions. Physiol. Behav. 13, 599-602.
274. Stricker, E.M. and Zigmond, M.J. (1984). Comments on effects of nigro-striatal dopamine lesions. Appetite 5, 266-267.
275. Stromberg, U. (1970). Dopa effects on motility in mice: potentiation by MK 485 and dexchlorpheniramine. Psychopharmacologia 18, 58-67.
276. Suzuki, M., Hirai, T., Ito, Y., Sakamoto, T., Oka, H., Kurita, A., and Inoue, K. (2008). Pramipexole-induced antecollis in Parkinson's disease. J. Neurol. Sci. 264, 195-197. (Pubitemid 350184083)
277. Tagliati, M., Martin, C., and Alterman, R. (2010). Lack of motor symptoms progression in Parkinson's disease patients with long-term bilateral subthalamic deep brain stimulation. Int. J. Neurosci. 120, 717-723.
278. Taguchi, Y., Takashima, S., and Tanaka, K. (2008). Pramipexoleinduced dropped head syndrome in Parkinson's disease. Int. Med. 47, 2011-2012.
279. Takatsuna, Y., Adachi-Usami, E., Ino, H., and Chiba, T. (1992). Effects of MPTP on the mouse retina. Nippon. Ganka. Gakkai. Zasshi. 96, 767-775.
280. Teitelbaum, P. and Epstein, A.N. (1962). The lateral hypothalamic syndrome: recovery of feeding and drinking after lateral hypothalamic lesions. Psychol. Rev. 69, 74-90.
281. The Parkinson Study Group. (2004). Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508.
282. Thompson, S., Lupi, D., Hankins, M.W., Peirson, S.N., and Foster, R.G. (2008). The effects of rod and cone loss on the photic regulation of locomotor activity and heart rate. Eur. J. Neurosci. 28, 724-729.
283. Thorpy, M.J. and Adler, C.H. (2005). Parkinson's disease and sleep. Neurol. Clin. 23, 1187-1208. (Pubitemid 41503071)
284. Trenkwalder, C., Hening, W.A., Montagna, P., Oertel, W.H., Allen, R.P., Walters, A.S., Costa, J., Stiasny-Kolster, K., and Sampaio, C. (2008). Treatment of restless legs syndrome: an evidencebased review and implications for clinical practice. Mov. Disord. 23, 2267-2302.
285. Uc, E.Y., Struck, L.K., Rodnitzky, R.L., Zimmerman, B., Dobson, J., and Evans, W.J. (2006). Predictors of weight loss in Parkinson's disease. Mov. Disord. 21, 930-936. (Pubitemid 44184592)
286. Umemura, A., Oka, Y., Okita, K., Matsukawa, N., and Yamada, K. (2011). Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions. J. Neurosurg. 114, 1701-1705.
287. Ungerstedt, U. (1971a). Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 367, 95-122.
288. Ungerstedt, U. (1971b). Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Suppl. 367, 49-68.
289. Ungerstedt, U. (1971c). Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl. 367, 1-48.
290. Ungerstedt, U. (1971d). Use of intracerebral injections of 6-hydroxydopamine as a tool for morphological and functional studies on central catecholamine neurons. In: 6-Hydroxydopamine and Catecholamine Neurones, T. Malmfors and H. Thoenen, eds. (Amsterdam: North Holland Publishing), pp. 315-322.
291. Ungerstedt, U. and Arbuthnott, G.W. (1970). Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigro-striatal dopamine system. Acta Physiol. Scand. 24, 485-493.
292. Ungerstedt, U., Ljungburg, L., and Ranje, C. (1977). Dopamine neurotransmission and the control of behaviour. In: Psychobiology of the Striatum, E.A. Cools, ed. (Amsterdam: Elsevier/North Holland Biomedical Press), pp. 85-97.
293. Uretsky, N.J. and Schoenfeld, R.I. (1970). Effects of L-Dopa on the locomotor activity of rats pretreated with 6-hydroxyDA. Nature New Biol. 234, 157-159.
294. Veki, A., Chong, P.N., Albanese, A., Rose, S., Chivers, J.K., Jenner, P., and Marsden, C.D. (1989). Further treatment with MPTP does not produce Parkinsonian in marmosets showing behavioural recovery from motor defi cits induced by an earlier exposure to the toxin. Neuropharmacology 28, 1089-1097. (Pubitemid 19254403)
295. Verhagen, L. (2011). Deep brain stimulation in Parkinson's disease: the basics. J. Acoust. Soc. Am. 130, 2409.
296. Vitek, J.L., Zhang, J., Hashimoto, T., Russo, G., and Baker, K.B. (2011). External pallidal stimulation improves Parkinsonian motor signs and modulates neuronal activity throughout the basal ganglia thalamic network. Exp. Neurol. 233, 581-586.
297. Voon, V., Schoerling, A., Wnzel, S., Ekanayake, V., Reiff, J., Trenkwalder, C., and Sixel-Döring, F. (2011). Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 28, 117.
298. Walker, H.C., Lyerly, M., Cutter, G., Hagood, J., Stover, N.P., Guthrie, S.L., Guthrie, B.L., and Watts, R.L. (2009). Weight changes associated with unilateral STN DBS and advanced PD. Parkinson. Relat. Disord. 15, 709-711.
299. Wang, E. (2011). Effect of deep brain stimulation on speech in Parkinson's disease: from research lab to clinic. J. Acoust. Soc. Am. 130, 2409.
300. Ward, C.D., Turpin, G., Dewey, M.E., Fleming, S., Hurwitz, B., Ratib, S., von Fragstein, M., and Lymbery, M. (2004). Education for people with progressive neurological conditions can have negative effects: evidence from a randomized control trial. Clin. Rehab. 18, 717-725. (Pubitemid 39545190)
301. Whittier, J.R. and Orr, A. (1962). Hyperkinesia and other physiological effects of caudate defi cits in albino rat. Neurology 12, 502-539.
302. Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., et al. (2003). Slower progression of Parkinson's disease with ropinerole versus levodopa: the REAL-PET study. Ann. Neurol. 54, 93-101. (Pubitemid 36764985)
303. Willis, G.L. (1987). Amine accumulation in Parkinson's disease and other disorders. Neurosci. Biobehav. Rev. 11, 97-105. (Pubitemid 17042720)
304. Willis, G.L., (2008). Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci. 19, 245-316.
305. Willis, G.L. and Armstrong, S.M. (1998). Orphan neurons and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res. Rev. 27, 177-242. (Pubitemid 28389309)
306. Willis, G.L. and Donnan, G.A. (1987). Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res. 402, 269-274. (Pubitemid 17005295)
307. Willis G.L. and Sandyk, R. (1992). Sensitivity of dopamine receptors in the lateral hypothalamus is altered in 6-hydroxydopamine treated rats. Int. J. Neurosci. 65, 198-207.
308. Willis, G.L. and Sandyk, R. (1993). Amphetamine-induced rotational behaviour in rats: relationship to hypothalamic and striatal degeneration. Int. J. Neurosci. 71, 135-146.
309. Willis, G.L. and Smith, G.C. (1982). The behavioural effects of intrahypothalamic multistage versus single injections of 6-hydroxydopamine. Brain Res. 245, 345-352. (Pubitemid 12038388)
310. Willis, G.L. and Smith, G.C. (1984). Dopamine neurone degeneration- like defi cits produced by intrahypothalamic dopamine injections. In: The Basal Ganglia (Melbourne, Australia: Plenum Publishing Corporation), pp. 431-442.
311. Willis, G.L. and Turner, E.J.D. (2007). Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol. Int. 24, 521-537. (Pubitemid 47026954)
312. Willis, G.L., Smith, G.C., and McGrath, B.P. (1983). Defi cits in locomotor behaviour and motor performance after central 6-hydroxydopamine or peripheral L-dopa. Brain Res. 266, 279-286. (Pubitemid 13080102)
313. Willis, G.L., Moore, C., and Armstrong, S.M. (2012). A historical justifi cation for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. Rev. Neurosci. 23, 199-226.
314. Wooten, G.F. and Collins, R.C. (1981). Metabolic effects of unilateral lesion of the substantia nigra. J. Neurosci. 3, 285-291. (Pubitemid 11011797)
315. Wright, W.G., Gurfinkel, V.S., King, L.A., Nutt, J.G., Cordo, P.J., and Horak, F.B. (2010). Axial kinaesthesia is impaired in Parkinson's disease: effects of levodopa. Exp. Neurol. 225, 202-209.
316. Yamadori, T. and Yamauchi, K.E. (1983). An experimental anatomical study on the optic nerve fi bers in the rat: courses of the accessory optic tract. Brain Res. 269, 41-46. (Pubitemid 13054450)
317. Yeh, P., Walters, A.S., and Tsuang, J.W. (2011). Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. Epub ahead of print. Oct, 26.
318. Zabek, M., Sobstyl, M., Koziara, H., Kadaziolka, B., Mossakowski, Z., and Dzierzecki, S. (2010). Bilateral subthalamic nucleus stimulation in the treatment of advanced Parkinson's disese. Five years personal experience. Neurol Neurochir. Pol. 44, 3-12.
319. Zigmond, M.J. and Stricker, E.M. (1972). Defi cits in feeding behavior after intraventricular injections of 6-hydroxydopamine in rats. Science 177, 1211-1214.